证券代码：600513 证券简称：联环药业 公告编号：2025-071 江苏联环药业股份有限公司 第九届监事会第六次临时会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召集与召开情况 江苏联环药业股份有限公司（以下简称"公司"或"联环药业"）第九届监 事会第六次临时会议于 2025 年 9 月 12 日以通讯方式召开，本次会议通知于 2025 年 9 月 8 日以电子邮件形式发出。会议应出席监事 3 名，实际出席监事 3 名，出 席会议人数符合《公司章程》的规定。本次监事会由公司监事会主席遇宝昌先生 主持，会议经过了适当的召集和通知程序，符合《中华人民共和国公司法》等相 关法律、法规及《公司章程》的规定，会议合法有效。 监事会认为： 联环药业（安庆）有限公司本次购买资产是为了保障公司长期稳定发展，提 高公司资产的稳定性和抗风险能力，本次交易以资产评估结果为定价依据，定价 合理公允。本次关联交易不会损害公司及股东特别是中小股东的利益，不会对公 司财务状况和经营成果产生不利影响；本次关联交易已经公司董事会审议 ...

证券代码：600513 证券简称：联环药业 公告编号：2025-070 江苏联环药业股份有限公司 第九届董事会第十五次临时会议决议公告 （一）审议通过《关于全资子公司购买资产暨关联交易的议案》 为保障公司长期稳定发展，通过合理配置土地及实物资产显著提高公司资产 的稳定性和抗风险能力，公司全资子公司联环药业（安庆）有限公司拟向公司控 股股东江苏联环药业集团有限公司控股孙公司普林斯（安庆）医药科技有限公司 购买部分房屋建（构）筑物及土地使用权。本议案已经 2025 年第三次独立董事 专门会议审议通过。 具体内容详见披露在上海证券交易所网站 www.sse.com.cn 的《联环药业关 于全资子公司购买资产暨关联交易的公告》（公告编号：2025-072） 本议案需提交公司股东会审议。 （表决情况：赞成 7 票，反对 0 票，弃权 0 票，回避 2 票，关联董事夏春 来先生、涂斌先生回避表决） 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召集与召开情况 江苏联环药业股份有限公司（以下简称"公司"或"联环药业"）第九届董 ...

Core Viewpoint - Lianhuan Pharmaceutical (600513.SH) aims to enhance its asset stability and risk resistance through the acquisition of real estate and land use rights, indicating a strategic move for long-term sustainable development [1] Group 1: Transaction Details - Lianhuan Pharmaceutical's wholly-owned subsidiary, Lianhuan (Anqing), plans to purchase certain buildings and land use rights from Printers (Anqing) [1] - The transaction price is set at 74.5 million RMB (excluding tax), based on the asset evaluation results from Tianyuan Asset Appraisal Co., Ltd [1]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical announced a transaction involving the purchase of certain real estate and land use rights from its controlling shareholder for 74.5 million RMB (excluding tax) [1] - The transaction is classified as a related party transaction and does not constitute a major asset restructuring as defined by the regulations [1] - The transaction has been approved by the company's board of directors and supervisory board, but it still requires approval from the shareholders' meeting and must go through state-owned asset approval and transfer registration procedures [1] Group 2 - The purpose of the transaction is to optimize resource allocation, expand asset scale, and enhance overall strength [1]

江苏联环药业股份有限公司 2025 年第二次临时股东会会议资料 江苏联环药业股份有限公司 2025 年第二次临时股东会会议资料 （股票代码：600513） 会议日期：二〇二五年九月十五日 - 1 - 江苏联环药业股份有限公司 2025 年第二次临时股东会会议资料 目 录 五、股东要求发言或就有关问题提出质询时，应先报告所持股份数量，每位股东发言 时间一般不超过 5 分钟。 | 股东会会议须知 ……………………………………………………………………………- 3 - | | --- | | 联环药业 2025 年第二次临时股东会会议基本情况及议程………………………………- 4 - | | 2025 年第二次临时股东会投票卡 …………………………………………………………- 6 - | | 议案一：《增加指定信息披露媒体、取消监事会并修订<公司章程>的议案》 ………- 7 - | | 议案二：《关于修订<关于控股股东为公司提供担保暨关联交易>的议案》 …………- 8 - | | 议案三：《关于修订<股东会议事规则>的议案》 ………………………………………- 9 - | | 议案四：《关于修订<董事会议事规则>的议案》 ...

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection [2] Group 1 - The approval involves the issuance of a "Drug Registration Certificate" for the product [2]

Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical has received approval from the National Medical Products Administration for its product "Famotidine Injection" [1] - Lianhuan Pharmaceutical's revenue composition for the year 2024 is as follows: 59.36% from pharmaceutical distribution, 40.38% from pharmaceutical manufacturing, and 0.26% from other businesses [1] - The current market capitalization of Lianhuan Pharmaceutical is 6 billion yuan [2]

Core Viewpoint - Recently, Lianhuan Pharmaceutical (600513.SH) received approval from the National Medical Products Administration for the drug registration certificate of Famotidine Injection, which is a medication that works by inhibiting gastric acid secretion and belongs to the class of histamine H2 receptor antagonists [1] Company Summary - Lianhuan Pharmaceutical has successfully developed Famotidine Injection, expanding its product portfolio in the pharmaceutical market [1] - The approval of Famotidine Injection indicates the company's commitment to enhancing its therapeutic offerings in the gastrointestinal treatment sector [1] Industry Summary - The approval of new drugs like Famotidine Injection reflects ongoing advancements in the pharmaceutical industry, particularly in the development of medications for gastrointestinal disorders [1] - The introduction of histamine H2 receptor antagonists is significant for addressing conditions related to excessive gastric acid secretion, which is a common health issue [1]

关于公司获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600513 证券简称：联环药业 公告编号：2025-069 江苏联环药业股份有限公司 截至本公告披露日，公司于 2025 年共获得 10 个生产批件，2 个临床批件。 三、对公司的影响 江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相 关情况公告如下： 二、药品的其他情况 法莫替丁注射液是一种通过抑制胃酸分泌发挥治疗作用的药物，属于组胺 H2 受体阻滞药。2024年度国内样本医院法莫替丁注射液销售额达4.91亿元人民 1 药品名称 法莫替丁注射液 剂型 注射剂 规格 2ml:20mg 申请事项 药品注册（境内生产） 注册分类 化学药品 3 类 处方药/非处方药 处方药 受理号 CYHS2400866 证书编号 2025S02673 药品批准文号 国药准字 H20255286 上市许可持有人 名称：江苏联环药业股份有限公司 地址：江苏省扬州市扬州生物 ...